Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill For Cannabinoid Therapies

Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies

ISRAEL: Intec Pharma, a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced the results from a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with cannabidiol (CBD) and tetrahydrocannabinol (THC), the two primary cannabinoids contained in Cannabis sativa. “We’re excited about these encouraging results from our Read the full article…

Marijuana’s Promise Of Profit Remains Elusive (For Now)

Those trials are all ongoing, so investors will need to rely on past trial data to make judgments on whether or not the market demand for GW Pharma's medicine will justify the company's $1.27 billion market cap.

NEW YORK: Excitement surrounding medical marijuana led to a significant run-up in GW Pharmaceuticals‘ share price earlier this year, but based on the company’s recently announced quarterly and fiscal full-year earnings results, the promise of marijuana profit remains far off in the distance. Planning for the future That’s because GW Pharma has only one marketed marijuana derived therapy, Read the full article…

GW Pharmaceuticals Closes U.S. Public Offering; Cannabis-Based Medicines Progress

Cannabis-based medicines progress.

NORTH CAROLINA:  Yesterday, Salisbury, UK-based GW Pharmaceuticals plc announced the closing of its public offering of 1.7 million American Depositary Shares on the NASDAQ Global Market. When taken together with the full exercise of options for another 255,000 ADSs by the underwriters at $86.83/ADS, the offering totaled $169.8 million. Although some of the ADRs were sold by Read the full article…

7 Things You Need To Know About Sativex

Recognizing their medical capacity, major pharmaceutical companies have put to use derivatives of the chemicals found in marijuana or their synthetic counterparts to address various ailments.

GREAT BRITAIN: Many are starting to hear about a marijuana-based pharmaceutical called Sativex. The drug, which comes as an oral spray, has already been approved in 24 countries as a treatment for multiple sclerosis. While yet to be approved in the United States, Sativex is legally available in countries like Canada, Australia, Britain and, most recently, Read the full article…